ESTA

Establishment Labs Holdings Inc. - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Establishment Labs Holdings Inc. is a global medical device company manufacturing and marketing silicone gel-filled breast implants, primarily under the Motiva Implants brand. The company operates manufacturing facilities in Costa Rica and sells products in the United States, Europe, the Middle East, Latin America, and Asia. The company received FDA approval to sell Motiva Implants in the U.S. in September 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 44.7% year-over-year, driven primarily by a $13.5 million increase in U.S. sales following FDA approval. International sales also grew, particularly in Asia-Pacific and Latin America.
• Profitability Improvement: Net loss narrowed by 35.4% to $13.4 million. Operating loss improved from $16.9 million to $6.5 million.
• Margin Expansion: Gross margin expanded to 70.7% from 67.2%, attributed to higher selling prices in the U.S. market, partially offset by increased inventory obsolescence reserves.
• Expense Trends: SG&A expenses rose 9.8% due to personnel, consulting, and freight costs. R&D expenses remained relatively flat. Interest expense increased to $7.1 million due to higher debt principal balances.
• Cash Flow: Net cash used in operating activities improved significantly to $4.3 million from $20.7 million in the prior year.

Guidance, Outlook, and Risks

Recent Financing (Subsequent Event): On April 30, 2026, the company entered into an Amended Credit Agreement providing up to $300 million in new term loans. The first tranche of $265 million was advanced to repay the previous $246.4 million debt obligation. The new debt carries an interest rate of 8.75% and matures in 2031.

Management Commentary: Management believes proprietary technologies in Motiva Implants drive revenue growth and result in favorable safety outcomes compared to competitors. The company expects to continue generating losses in the near term while investing in commercialization and R&D.

Risks and Contingencies:

• Regulatory & Safety: The medical device industry is heavily regulated. Negative publicity regarding breast implant safety (e.g., ALCL, recalls of competitor products) could reduce demand.
• Supply Chain: The company relies on a single-source supplier (Avantor) for medical-grade silicone, representing 53.7% of total purchases in Q1 2026.
• Liquidity: While the company recently refinanced its debt, it has an accumulated deficit of $509.1 million and relies on future commercial success to achieve profitability.
• Contingent Consideration: A liability of $4.4 million related to the 2024 acquisition of Motiva Benelux and Motiva NL remains outstanding, subject to revenue performance targets.

Investor Verification Checklist

• Debt Refinancing Terms: Verify the specific covenants and interest rate step-up/down mechanisms in the new $300 million credit agreement signed in April 2026.
• U.S. Market Penetration: Monitor the sustainability of the 44.7% revenue growth, specifically the contribution from the U.S. market which now accounts for over 32% of revenue.
• Single-Source Supplier Risk: Assess the stability of the relationship with Avantor and the potential impact of price increases or supply interruptions.
• Contingent Liability: Track the $4.4 million contingent consideration payable related to the European acquisition and its impact on future cash flows.
• Inventory Valuation: Review the $4.9 million provision for inventory obsolescence and the $16.2 million in consigned inventory for potential write-down risks.